A Phase 2 interventional study of BTA798 and Placebo in Rhinovirus, sponsored by Biota Scientific Management Pty Ltd. Completed at 43 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-05-31.
Sponsored by Biota Scientific Management Pty Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on
Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.
Biota Scientific Management Pty Ltd is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BTA798
Drug: Placebo
BTA798 twice daily
Placebo twice daily
Also known as: Glucose
Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire
Daily Change in WURSS-21 Severity Score Averaged over Days 2 to 4. The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.
Time frame: Days 2-4
| Milestone | BTA798 | Placebo |
|---|---|---|
| Started | 155 | 145 |
| Completed | 144 | 140 |
| Not completed | 11 | 5 |
Daily Change in WURSS-21 Severity Score Averaged over Days 2 to 4. The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.
| Scores on a scale | BTA798 | Placebo |
|---|---|---|
| Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire | -9.12 ± 1.403 | -5.11 ± 1.184 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BTA798 | 0/154 (0%) | 0/154 (0%) | 22/154 (14.3%) |
| Placebo | 0/145 (0%) | 0/145 (0%) | 18/145 (12.4%) |
| Event | BTA798 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 7/154 | 6/145 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/154 | 5/145 |
| SinusitisInfections and infestations | 5/154 | 4/145 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/154 | 3/145 |
Safety population - all randomized subjects who received at least 1 dose of investiational product.
| Age, Continuous(years) | BTA798 | Placebo | Total |
|---|---|---|---|
| Mean | 40.6 ± 14.34 | 42.0 ± 13.69 | 41.3 ± 14.02 |
| Sex: Female, Male(Participants) | BTA798 | Placebo | Total |
|---|---|---|---|
| Female | 114 | 95 | 209 |
| Male | 40 | 50 | 90 |
| Region of Enrollment(participants) | BTA798 | Placebo | Total |
|---|---|---|---|
| United States | 154 | 145 | 299 |
The record gives a start of Aug 2010, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 5 years 3 months after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vapendavir
Biota Scientific Management Pty Ltd